Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare progression-free survival (PFS) of patients with
advanced, recurrent or metastatic endometrial cancer who have received one, but not more than
two, prior lines of chemotherapy either as adjuvant therapy or treatment for advanced
disease, and then when treated with ridaforolimus or the investigators' choice of progestin
or chemotherapy.